Table III.
Adverse events
| Grade 3/4 toxicities (induction phase) | RH (N=17) | RB (N=35) |
|---|---|---|
| Anaemia | 59% | 8.6% |
| Neutropenia | 65% | 34% |
| Febrile neutropenia | 29% | 14% |
| Thrombocytopenia | 71% | 17% |
| Hypokalaemia | 29% | 5.7% |
| Hypophosphataemia | 24% | 2.9% |
| Hyperglycaemia | 12% | 0% |
| ALT increased | 5.9% | 0% |
| AST increased | 5.9% | 0% |
| Catheter-related infection | 5.9% | 2.9% |
| Dehydration | 5.9% | 0% |
| Diarrhoea | 5.9% | 0% |
| Epistaxis | 5.9% | 0% |
| Nausea | 5.9% | 0% |
| Rash | 5.9% | 2.9% |
| Syncope | 5.9% | 0% |
ALT, alanine transaminase; AST, aspartate transaminase; RB, rituximab plus bendamustine; RH, R-HyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate)